Condition: Mild to Moderate Asthma · Sponsor: Prana Therapies Inc
Phase 1 of this study will consist of 2 parts * Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC). * Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously. Phase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.
This description comes directly from the study's public registry record.
Linear site contact · +61 (0)8 6382 5110 · enquiries@linear.org.au
Always discuss trial participation with your own doctor first.
| Emertitus Research Sydney | Botany, New South Wales, Australia | Not Yet Recruiting |
| Emeritus Research Camberwell | Camberwell, Victoria, Australia | Not Yet Recruiting |
| Linear | Joondalup, Western Australia, Australia | Not Yet Recruiting |
| Linear | Nedlands, Western Australia, Australia | Recruiting |
| PCRN Waikato, Nawton | Hamilton, Auckland, New Zealand | Not Yet Recruiting |
| Pacific Clinical Research Network-Auckland | Takapuna, Auckland, New Zealand | Not Yet Recruiting |
| PCRN Wellington, Ebdentown | Upper Hutt, Auckland, New Zealand | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07245368